prodchem
Aug 20, 2026
San Diego's biotech ecosystem continues to demonstrate strong company-formation and venture activity in 2026, with Khartis Therapeutics' emergence from stealth and $95 million in total funding providing one of the year's more notable examples.
Khartis, a San Diego-based biotechnology company founded in 2024, emerged publicly in August 2026 with a focus on oral small-molecule medicines for immune-mediated and chronic diseases. Its lead program targets thyroid eye disease, giving the company a differentiated entry point within the competitive immunology market.
The launch is significant not only because of its financing. It provides another data point for assessing whether San Diego can continue to compete with Boston, the San Francisco Bay Area, and other major U.S. biotechnology hubs for new-company formation, venture capital, scientific talent, and drug-development platforms.
San Diego is already one of the United States' major life-sciences clusters, supported by research institutions, established biotechnology companies, specialized talent, and an active venture ecosystem. Recent industry analysis continues to describe the region as a top U.S. biotech hub, with approximately $4.8 billion in venture funding referenced for the ecosystem.
That creates an important foundation for new-company formation.
A strong biotech launch ecosystem typically depends on:
Experienced scientific founders
University and research infrastructure
Venture capital availability
Pharmaceutical talent
Clinical-development expertise
Specialized laboratory facilities
Follow-on financing
Potential acquisition partners
San Diego has many of these ingredients in relatively concentrated form.
Khartis is particularly notable because its launch combined company formation, experienced pharmaceutical leadership, substantial financing, and a differentiated therapeutic strategy.
The company emerged with approximately $95 million in total capital, including a new $50 million Series B.
Its leadership also brings significant pharmaceutical drug-discovery experience. Khartis' scientific leadership includes former Pfizer personnel, while members of the team previously worked together at XinThera before that company was acquired by Gilead Sciences.
That type of founder profile is valuable to regional biotech ecosystems because experienced drug developers can repeatedly form companies, attract investors, and translate scientific programs into clinical development.
A precise ranking based purely on 2026 biotech launch counts is difficult because there is no single standardized public database that captures every stealth company, spinout, financing-backed launch, and newly incorporated biotech.
A more useful approach is to rank the hubs according to the broader ecosystem supporting company formation.
Featured Product
Greater Boston remains the strongest U.S. benchmark for biotech company formation.
Its advantages include:
Exceptional academic research
Dense pharmaceutical presence
Deep venture capital
Large scientific workforce
Frequent biotech spinouts
Extensive clinical-development infrastructure
The region's combination of research and capital makes it particularly difficult for other hubs to match on overall formation density.
The Bay Area remains another dominant U.S. biotech ecosystem.
Its strengths include:
Stanford and UCSF research networks
Strong venture capital
Technology and biotech convergence
AI-enabled drug discovery
Experienced entrepreneurs
Large pharmaceutical and biotechnology presence
The region is especially strong where biotechnology intersects with computational biology, AI, and platform technologies.
San Diego remains highly competitive because of its combination of:
UC San Diego
Scripps Research
Established biotech companies
Pharmaceutical talent
Specialized venture investors
Concentrated life-sciences infrastructure
Khartis is a useful 2026 example of the ecosystem's ability to support a company from formation through substantial private financing.
Cities including New York/New Jersey, Philadelphia, Research Triangle, Seattle, and Los Angeles also maintain significant biotechnology activity.
Their relative strength varies by therapeutic category, academic infrastructure, venture capital, and proximity to pharmaceutical companies.
San Diego's biggest advantage may not be the absolute number of new companies.
It is the quality and concentration of the ecosystem.
The region has produced companies across:
Oncology
Rare disease
Immunology
Genomics
Cell therapy
Gene therapy
Neuroscience
Drug-discovery platforms
This diversity gives founders access to specialized talent and investors without requiring them to relocate to Boston or the Bay Area.
One of the most important indicators of a mature biotech hub is the ability of experienced teams to create multiple companies over time.
The Khartis example illustrates this dynamic.
Several members of its leadership team had previously worked together at XinThera, which was acquired by Gilead in 2023.
This creates a form of entrepreneurial recycling:
Successful biotech → acquisition → experienced founders → new company → new financing → new therapeutic platform
Over time, this cycle can strengthen a regional ecosystem even when individual companies disappear through acquisitions.
A biotech company technically "launching" with limited funding is less significant than one that launches with enough capital to advance a credible therapeutic program.
Khartis therefore stands out because its public emergence was accompanied by approximately $95 million in total funding.
This provides a stronger signal of ecosystem strength than a simple incorporation count.
For competitive intelligence, useful metrics include:
Number of new companies
Median launch financing
Total venture funding
Number of Series A/B rounds
Clinical-stage companies created
Founder experience
Follow-on financing
Pharmaceutical partnerships
Metric | Boston | Bay Area | San Diego |
|---|---|---|---|
Company formation | Very strong | Very strong | Strong |
Venture capital | Very strong | Very strong | Strong |
Academic research | Exceptional | Exceptional | Exceptional |
Pharma talent | Exceptional | Very strong | Strong |
AI/biotech convergence | Strong | Exceptional | Growing |
Clinical biotech | Exceptional | Very strong | Strong |
Founder recycling | Very strong | Very strong | Strong |
Ecosystem concentration | Exceptional | Exceptional | Strong |
The table highlights why San Diego should be viewed as a top-tier ecosystem rather than simply a secondary biotech market.
Khartis is developing oral small-molecule medicines for immunological and chronic diseases.
Its lead program is an oral selective IGF-1R inhibitor for thyroid eye disease, which the company describes as a potentially more convenient alternative to existing treatment approaches.
That focus is strategically interesting because San Diego's biotech ecosystem increasingly spans both established therapeutic categories and differentiated drug-discovery approaches.
A successful clinical program could therefore provide another example of San Diego companies developing specialized therapies rather than competing solely in crowded platform categories.
Companies tracking U.S. biotech hubs should monitor several indicators.
Track companies emerging from stealth or university and pharmaceutical spinouts.
Compare the amount of capital raised at formation.
Experienced founders can provide a stronger signal of development capability.
A newly formed company already positioned for clinical development is more significant than a pre-discovery startup.
Track pharmaceutical venture arms and specialist biotech investors participating in new-company financings.
A company's ability to raise subsequent rounds provides a useful test of ecosystem durability.
Biotech ecosystems can weaken when venture capital contracts or research funding falls.
San Diego's diversification may provide some protection.
The region contains:
Large established companies
Venture-backed startups
Research institutions
Contract research organizations
Platform companies
Diagnostics businesses
Life-sciences suppliers
This means the ecosystem is not dependent on a single therapeutic category or one source of capital.
The U.S. biotech market has shown signs of renewed investor interest in 2026, including a rebound in biotech IPO activity.
For example, Latigo Biotherapeutics and BlossomHill Therapeutics launched U.S. IPOs in August 2026, signaling improved access to public-market capital, although broader macroeconomic risks remain.
That backdrop is relevant to San Diego because stronger exit and financing conditions can encourage founders and investors to launch new companies.
San Diego could strengthen its competitive position if it continues to produce:
More clinical-stage startups
Larger Series A and B financings
Successful biotech exits
Pharmaceutical partnerships
University spinouts
Repeat founders
Platform companies with global relevance
The most important metric will ultimately be outcomes, not launch volume.
A smaller number of well-funded companies that reach clinical milestones or generate acquisitions can be more economically significant than a much larger number of lightly funded startups.
A growing biotech ecosystem also creates demand for specialized supply-chain services.
Biotechnology companies require:
Pharmaceutical intermediates
Excipients
Solvents
Laboratory chemicals
Research materials
Specialized manufacturing inputs
Clinical-trial supply chains
As more companies advance from discovery into clinical development, demand for reliable specialty-chemical and pharmaceutical-material suppliers can increase.
Khartis Therapeutics' emergence provides another useful benchmark for San Diego's 2026 biotech ecosystem.
The company's $95 million in total funding, experienced leadership, and focused immunology strategy demonstrate that San Diego can continue to produce new biotechnology companies capable of attracting substantial private capital.
San Diego still faces intense competition from Boston and the Bay Area, which possess deeper venture networks and enormous concentrations of scientific institutions and pharmaceutical companies.
But the relevant comparison is increasingly about company quality, financing depth, founder experience, and clinical execution, rather than raw startup counts.
The strongest intelligence signal is therefore not simply that another biotech launched in San Diego.
It is that experienced pharmaceutical scientists continue to recycle into new, well-funded companies in the region.
If that pattern persists, San Diego should remain one of the most important U.S. biotech formation hubs through the remainder of 2026 and beyond.
Khartis Therapeutics emerged from stealth in 2026 with approximately $95 million in total funding.
The San Diego company focuses on oral small-molecule therapies for immunological and chronic diseases.
Its lead program targets thyroid eye disease with an oral selective IGF-1R inhibitor.
San Diego remains a top-tier U.S. biotech ecosystem with strong research, venture, pharmaceutical, and founder networks.
Boston and the Bay Area remain the strongest benchmarks for overall U.S. biotech formation and capital depth.
San Diego's founder-recycling dynamic is an important competitive advantage.
Financing quality and clinical progress are more meaningful indicators than startup counts alone.
Continued biotech IPO and venture activity could support additional company formation across major U.S. hubs.
Found this useful?
Continue Reading
C&EN's August 18 Business Watch highlights two defining 2026 industry themes: BASF's historic Ludwigshafen workforce contraction and Khartis Therapeutics' launch, offering a snapshot of chemical restructuring and pharmaceutical innovation.
Eli Lilly's retatrutide enforcement campaign highlights why pharmaceutical manufacturers and regulatory agencies increasingly need coordinated strategies to address illicit compound markets. Faster market development is creating new challenges around monitoring, traceability and enforcement.
Eli Lilly's 2026 retatrutide crackdown offers a new benchmark for measuring the rapidly expanding illicit weight-loss drug market against prior-year GLP-1 enforcement and seizure data.
